MicroRNAs in cancer: from developmental genes in worms to their clinical application in patients
Open Access
- 9 July 2015
- journal article
- review article
- Published by Springer Nature in British Journal of Cancer
- Vol. 113 (4), 569-573
- https://doi.org/10.1038/bjc.2015.253
Abstract
Several discoveries have paved the way to personalise cancer medicine and a tremendous gain of knowledge in genomics and molecular mechanisms of cancer progression cumulated over the last years. Big stories in biology commonly start in a simple model system. No wonder microRNAs have been identified as regulators of embryonic development in the nematode Caenorhabditis elegans. From the first identification in worms to the first-in-man microRNA-based clinical trial in humans, almost 20 years passed. In this review we follow the story of understanding microRNA alterations in cancer, describe recent developments in the microRNA field and critically discuss their potential as diagnostic, prognostic and therapeutics factors in cancer medicine. We will explain the rationale behind the use of microRNAs in cancer diagnosis and prognosis prediction, but also discuss the limitations and pitfalls associated with this. Novel developments of combined microRNA/siRNA pharmacological approaches will be discussed and most recently data about MXR34, the first-tested microRNA drug will be described.Keywords
This publication has 29 references indexed in Scilit:
- The clinical and biological significance of MIR-224 expression in colorectal cancer metastasisGut, 2015
- miR-Test: A Blood Test for Lung Cancer Early DetectionJNCI Journal of the National Cancer Institute, 2015
- Lessons from miR-143/145: the importance of cell-type localization of miRNAsNucleic Acids Research, 2014
- MiR-200a regulates epithelial to mesenchymal transition-related gene expression and determines prognosis in colorectal cancer patientsBritish Journal of Cancer, 2014
- Therapeutic Synergy between microRNA and siRNA in Ovarian Cancer TreatmentCancer Discovery, 2013
- Assessing sample and miRNA profile quality in serum and plasma or other biofluidsMethods, 2012
- A Second-Generation MicroRNA-Based Assay for Diagnosing Tumor Tissue OriginThe Oncologist, 2012
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion SequencingNew England Journal of Medicine, 2012
- MicroRNAs in body fluids—the mix of hormones and biomarkersNature Reviews Clinical Oncology, 2011
- Regulation of Heparin-Binding EGF-Like Growth Factor by miR-212 and Acquired Cetuximab-Resistance in Head and Neck Squamous Cell CarcinomaPLOS ONE, 2010